ArticleCurrent drug delivery2025
Electrospun Nanofiber Films Containing Hesperidin and Ofloxacin for the Inhibition of Inflammation and Psoriasis: A Potential
Article in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Core-Sheath Nanofibers From a Modified Coaxial Electrospinning for Transdermal Delivery of Finasteride.ChemistryOpen · 2026Article
- Nanodelivery of Gentiopicroside for Inflammatory Skin Lesions: Insights from Psoriasis and Diabetic Foot Ulcers.International journal of nanomedicine · 2026Review
- Waterproof Fabric with Copper Ion-Loaded Multicompartmental Nanoparticle Coatings for Jellyfish Repellency.Pharmaceutics · 2025Article
- A Modified Triaxial Electrospinning for a High Drug Encapsulation Efficiency of Curcumin in Ethylcellulose.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNanofiber (NF) films have emerged as a promising alternative for treating psoriasis. Based on their specific characteristics, they have distinguished themselves from other topical dosage forms, such as hydrogels, foams, and sponges. This research looks at making biocompatible and biodegradable nanofibers out of polyvinyl alcohol (PVA) and gelatin and adding hesperidin (HPN) and ofloxacin (OFX) as medicine.
methodsHPN-OFX-integrated nanofiber (HPN-OFXNF) films were prepared using electrospinning. Subsequently, the surface morphology, entrapment efficiency, in vitro drug diffusion, and antimicrobial, anti-inflammatory, and anti-psoriasis properties were investigated.
resultsScanning electron microscopy (SEM) analysis revealed that the produced nanofibers exhibited smooth surfaces with diameters from 50.67 to 114.4 nm, entrapment efficiencies from 69.3 ± 1.8% for OFX and 45.63 ± 1.6% for HPN. At the end of 48 h, nanofibers showed 90.8 ± 2.4% of OFX and 97.3± 3.1% of HPN release. In vitro, antimicrobial testing of the films demonstrated 24.89 ± 3.2 and 42.46 ± 4.4 mm zones of inhibition against E. coli and S. aureus. The total antioxidant activity of HPN is 198.67±2.38 (μ mol AAE/mg HPN), and HPN-OFXNF is 271.12 ± 3.56 (μ mol AAE/mg HPN-OFXNF), and their IC50 values against HaCaT cell growth of 80.5 ± 2.5 and 64.6 ± 3.4 μg/ml, respectively. DISCUSSION: HPN-OFXNFs have been developed successfully by the electrospinning method with moderate entrapment efficiencies, showing a biphasic trend of an early burst trailed by a sustained pattern of drug release, depending on the surface area and diameter of the fibers. Enhanced zones of inhibition and anti-inflammatory efficacy of NFs in comparison with their pure counterparts have been demonstrated to be beneficial. Stronger antioxidant efficacy, inducing anti-proliferation and promoting apoptosis in human keratinocytes, has made them the best versions over pure drug compounds.
conclusionThis therapy, which includes a combined anti-inflammatory and antibacterial treatment strategy with an innovative drug delivery system, has proven to be a promising development in treating psoriasis.
Indexed as
Identifiers
40353404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.